Did Your Laidlaw and Company Broker Recommend Cytori Therapeutics, Inc. (CYTX)?

Soreide Law Group has received calls from clients who purchased Cytori Therapeutics, Inc. (CYTX) and have suffered significant stock losses.  This security was offered by brokers at Laidlaw and Company, who were also the underwriter of the offering. Newly issued securities are typically more volatile than older more established companies, and if as an investor you were not looking to speculate this may have been an unsuitable recommendation to you by your Laidlaw and Company stock broker.
According to Yahoo Finance, Cytori Therapeutics, Inc. (CYTX), a therapeutics company, together with its subsidiaries, develops regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for various medical conditions. It also sells Celution cell processing systems, StemSource cell and tissue banking systems, and surgical accessories and instrumentation to hospitals, clinics, physicians, researchers, and other customers for commercial and research purposes through a combination of a direct sales force, third-party distributors, independent sales representatives, and licensees. In addition, the company markets and sells its proprietary enzymatic reagents under the Celase and Intravase brands. It has operations in the Americas, Japan, EMEA, and the Asia Pacific. Cytori Therapeutics, Inc. was founded in 1996 and is headquartered in San Diego, California.
CYTX traded in February of 2014 at around 47.25, and today it is trading at approximately 0.28.
If you experienced stock losses in Cytori Therapeutics, Inc. (CYTX) due to the recommendation of a Laidlaw and Company securities broker, call Soreide Law Group for a free consultation with an experienced securities lawyer regarding the possible recovery of your investment losses through a FINRA arbitration at: 888-760-6552.
Soreide Law Group represents clients nationwide before FINRA.  We operate on a contingency fee basis, no fee if no recovery.